You are viewing: North America Immunoassay Market analysis
Part of: Immunoassay Market (Global)

The North America Immunoassay Market was valued at $7906.96 Million in 2025 and projected to reach to $11308.33 Million by 2030, representing a compound annual growth rate of CAGR 7.4%. The North American immunoassay market is positioned for sustained growth through 2030, driven by aging demographics, rising prevalence of chronic diseases, and increasing healthcare spending across the region.

North America Immunoassay Market Trends and Insights

  • Asia Pacific's immunoassay sector is driven by rising healthcare expenditure, increasing prevalence of chronic diseases, and expanding diagnostic infrastructure across emerging economies.
  • The region's growth trajectory outpaces the global average, reflecting strong demand for point-of-care testing and laboratory automation solutions. Asia Pacific's immunoassay market benefits from a large patient population, growing awareness of early disease detection, and government initiatives to strengthen healthcare systems.
  • Key markets within Asia Pacific, including China, India, Japan, and Southeast Asia, are investing heavily in diagnostic capabilities and clinical laboratory modernization.
  • The forecast period through 2030 indicates sustained momentum as Asia Pacific continues to adopt advanced immunoassay technologies and expand access to diagnostic services across urban and emerging healthcare settings..

Key Market Statistics

  • CAGR (2025-2030) CAGR 7.4%
  • Market Size, 2025 ~USD 7906.96 Million
  • Forecast, 2030 ~USD 11308.33 Million
  • Geography North America

North America Immunoassay Market Overview

US Market Dominance :

The United States commands the North American immunoassay market with a valuation of $11,474.68 million in 2025, representing approximately 93% of the regional market share and driving significant innovation in diagnostic technologies.

Strong Regional Growth Trajectory :

North America's immunoassay market is expanding at a 7.4% CAGR, outpacing the global average of 6.1%, fueled by advanced healthcare infrastructure, high diagnostic adoption rates, and substantial R&D investments.

Canadian Market Contribution :

Canada represents a secondary but significant market at $1,565.18 million in 2025, supported by universal healthcare coverage, increasing chronic disease prevalence, and growing demand for point-of-care testing solutions.

Regulatory Excellence & Innovation Hub :

North America benefits from stringent FDA and Health Canada regulations that drive quality standards, coupled with a robust ecosystem of diagnostic manufacturers and biotech companies accelerating immunoassay technology advancement.

North America Immunoassay Market Dynamics

  • The US market's maturity combined with technological innovation in automation and multiplex testing capabilities creates strong expansion opportunities.
  • Canada's growing diagnostic infrastructure and healthcare modernization initiatives further support regional momentum. Key growth catalysts include the shift toward personalized medicine, expansion of point-of-care testing in clinical settings, and integration of immunoassay platforms with digital health solutions.
  • Competitive pressures and consolidation among diagnostic manufacturers will likely accelerate product innovation and market penetration, particularly in emerging applications such as biomarker detection and infectious disease screening..

Related Ecosystem

In Vitro Diagnostics

Top Technologies
  • Polymerase Chain Reaction (PCR)
  • Enzyme-Linked Immunosorbent Assay (ELISA)
  • Dna Microarrays
  • Assay Kits
  • Microarrays
Top Companies
  • ROCHE HOLDINGS AG
  • Thermo Fisher Scientific Inc.
  • Danaher Corporation
  • Abbott Laboratories
  • Biomerieux s.a.

    Medical Devices

    Top Technologies
    • Polymerase Chain Reaction (PCR)
    • Magnetic Resonance Imaging (MRI)
    • Disposable Autoinjectors
    • Pulse Oximeters
    • Blood Pressure Monitors
    Top Companies
    • Medtronic plc
    • Abbott Laboratories
    • Stryker Corporation
    • Becton, Dickinson and Company
    • JOHNSON & JOHNSON

      Key Takeaways

      • Asia Pacific immunoassay market valued at $7,906.96M in 2025, expanding to $11,308.33M by 2030 at 7.4% CAGR
      • Asia Pacific's growth rate of 7.4% exceeds the global CAGR of 6.1%, driven by emerging market expansion and healthcare infrastructure investment
      • Rising chronic disease prevalence and government healthcare initiatives are accelerating immunoassay adoption across Asia Pacific
      • Point-of-care testing and laboratory automation are key growth drivers reshaping Asia Pacific's diagnostic landscape through 2030

      Immunoassay Market Report Scope

      Report Metric Details
      Base Year 2025
      Fastest Growing Segment CLIA (Technology)
      Forecast Period 2025–2030
      Growth Rate CAGR of 6.1% from 2025 to 2030
      Largest Segment REAGENTS & KITS (Product)
      Market Size Base Year (Billions) ~USD 35.48 (2025)
      Revenue Forecast (Billions) ~USD 47.7 (2030)
      Segments Covered Product, Type, Purchase Mode, Technology, Specimen, Application

      North America Immunoassay Market Report Segmentation

      6 segment dimensions are covered across the global market.

      By Product

      • Analyzers
      • Reagents & Kits

      By Type

      • Clia Reagents & Kits
      • Closed-Ended Systems
      • Elisa Reagents & Kits
      • Elispot Reagents & Kits
      • Ifa Reagents & Kits
      • Open-Ended Systems
      • Other Reagents & Kits
      • Rapid Test Reagents & Kits
      • Western Blot Reagents & Kits

      By Purchase Mode

      • Outright Purchase
      • Rental Purchase

      By Technology

      • Clia
      • Elisa
      • Elispot
      • Ifa
      • Other Technologies
      • Rapid Tests
      • Western Blotting

      By Specimen

      • Blood
      • Other Specimens
      • Saliva
      • Urine

      By Application

      • Allergy Diagnostics
      • Autoimmune Disorders
      • Blood Screening
      • Bone & Mineral Disorders
      • Cardiology
      • Drug Monitoring & Testing
      • Endocrinology
      • Infectious Diseases
      • Newborn Screening
      • Oncology
      • Other Applications

      Target Audience

      • Diagnostic Manufacturers : In vitro diagnostics and immunoassay platform manufacturers need North American market data to optimize product portfolios, identify growth segments, and align manufacturing strategies with regional demand patterns.
      • Healthcare Providers & Laboratories : Hospital networks, clinical laboratories, and diagnostic centers require market insights to evaluate immunoassay technology investments, benchmark utilization rates, and plan capital expenditures aligned with regional growth.
      • Investors & Private Equity : Investment firms and venture capitalists targeting the diagnostics sector need North American market validation, growth forecasts, and competitive dynamics to assess acquisition targets and portfolio company valuations.
      • Pharmaceutical & Biotech Companies : Pharma firms developing companion diagnostics and biomarker assays require North American market sizing and adoption trends to support clinical trial planning and commercialization strategies.
      • Healthcare Consultants & Advisors : Management consulting firms and healthcare advisors need regional market data to support client strategy development, competitive analysis, and market entry planning in the North American immunoassay sector.

      Key Companies in the North America Immunoassay Market

      CompanyHQOwnershipStrongest segments
      PATHEON INCNetherlandsPrivate CompanyDrug Product Services (oral, sterile, packaging, lifecycle),Pharmaceutical Development Services (preclinical to clinical),Drug Substance Services (small-molecule and biologics APIs),
      ALERE INCUnited StatesPrivate CompanyInfectious disease diagnostics (rapid and serology, including ELISA and automated systems),Cardiometabolic and critical care point-of-care (blood gas, lipids, glucose, D-dimer, troponin, diabetes),Toxicology and workplace drug testing (devices, reagents, lab services, alcohol tests),
      FLUOR CORPORATIONUnited StatesPublic CompanyEnergy Solutions (oil, gas, chemicals, LNG, power, energy transition),Urban Solutions (advanced technologies, life sciences, mining and metals, infrastructure, staffing, maintenance),Mission Solutions (government, nuclear remediation, nuclear security, logistics, mission-critical O&M),
      CEPHEID INC.United StatesPrivate CompanyInfectious disease & healthcare-associated infection assays (Xpert on GeneXpert),Virology assays (including emergency use authorization tests),Oncology and genetics assays,
      IMMUCOR, INC.United StatesPrivate CompanyTransfusion (serology instruments and reagents, including NEO, Echo, Capture),Transplant & Molecular (HLA, HPA assays, Array Imaging System, BASIS, platelet-focused products),Other / Services and Ancillary Products,
      UNILABSSwitzerlandPrivate CompanyRoutine & Specialty Laboratory Testing,Medical Imaging,Pathology & Centres of Excellence (IVF, Fertility, Pregnancy, Targeted Diagnostics),
      EIKEN CHEMICAL CO., LTD.JapanPublic CompanyFecal immunochemical test (FIT) reagents and analyzers,Microbiological reagents and food/environmental microbiology,Urinalysis test strips and analyzers,
      ABBOTTUnited StatesPublic CompanyDiagnostic Products,Medical Devices,Nutritional Products,
      SIEMENS HEALTHINEERS AGGermanyPublic CompanyImaging,Diagnostics,Varian (Oncology),
      DANAHERUnited StatesPublic CompanyBiotechnology (bioprocessing and related solutions),Life Sciences (analytical instruments, genomics, and lab automation),Diagnostics (clinical instruments and consumables),
      THERMO FISHER SCIENTIFIC INC.United StatesPublic CompanyLife Sciences Solutions,Analytical Instruments,Specialty Diagnostics,
      REVVITYUnited StatesPublic CompanyDiagnostics instruments and systems,Diagnostics reagents, assays, and consumables,Life science reagents and genomic workflow tools,
      DIASORIN S.P.A.ItalyPublic CompanyImmunodiagnostics – Infectious and Gastrointestinal Diseases,Immunodiagnostics – Endocrinology, Metabolic Disorders, Tumor Markers, Oncology,Molecular Diagnostics – Simplexa and Congenital CMV,
      BIO-RAD LABORATORIES, INC.United StatesPublic CompanyClinical Diagnostics,Life Science Research Tools,Other / Informatics & Software,
      QUIDELORTHO CORPORATIONUnited StatesPublic CompanyLabs (clinical chemistry and immunoassay),Transfusion Medicine,Point of Care,
      BIOMÉRIEUXFrancePublic CompanyClinical microbiology & AST (VITEK, CHROMID, ETEST, culture media, BACT/ALERT),Syndromic and molecular diagnostics (BIOFIRE, SPOTFIRE, ARGENE, EMAG/NUCLISENS),Immunoassays & biomarkers (VIDAS, Hybiome CLIA),
      QIAGENNetherlandsPublic CompanySample technology consumables and instruments,Molecular diagnostics assays (TB, immune response, oncology, sexual and reproductive health),Research PCR and enzymes (qPCR, digital PCR, RT-PCR, configured solutions),
      SYSMEX CORPORATIONJapanPublic CompanyHematology analyzers & reagents,Coagulation diagnostics,Urinalysis, blood gas, electrolyte,
      AGILENT TECHNOLOGIES, INC.United StatesPublic CompanyLife Sciences and Diagnostics Markets,Agilent CrossLab,Applied Markets,
      SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.ChinaPublic CompanyPatient monitoring and life support (monitoring, ventilators, defibrillation, AED, anesthesia),Ultrasound and medical imaging (ultrasound, radiology, endoscope camera system),In-vitro diagnostics (CLIA, chemistry, hematology, laboratory diagnostics),

      PATHEON INC

      Patheon Inc. is a Netherlands-based pharmaceutical manufacturing company with 9,100 employees. Operating as a private company, it provides contract development and manufacturing services to the pharmaceutical industry.

      ALERE INC

      Alere Inc. is a United States-based diagnostics company founded in 1981 with 9,700 employees. Operating as a private company, it specializes in rapid diagnostic testing solutions for healthcare markets.

      FLUOR CORPORATION

      Fluor Corporation is a United States-based engineering and construction company founded in 1912 with 22,995 employees. As a public company, it provides design, engineering, procurement, and construction services across multiple industries.

      CEPHEID INC.

      Cepheid Inc. is a United States-based molecular diagnostics company founded in 1996 with 1,700 employees. Operating as a private company, it develops and manufactures automated molecular testing systems.

      IMMUCOR, INC.

      Immucor, Inc. is a United States-based immunohematology company founded in 1982 with 1,125 employees. As a private company, it specializes in blood bank and transfusion medicine diagnostic solutions.

      UNILABS

      Unilabs is a Switzerland-based clinical laboratory services company founded in 1987 with 1,897 employees. As a private company, it operates diagnostic laboratories across multiple European countries.

      EIKEN CHEMICAL CO., LTD.

      Eiken Chemical Co., Ltd. is a Japan-based diagnostics and pharmaceutical company founded in 1939 with 696 employees. As a public company, it manufactures in vitro diagnostic reagents and pharmaceutical products.

      ABBOTT

      Abbott is a United States-based healthcare company founded in 1888 with 115,000 employees. As a public company, it develops and manufactures diagnostics, medical devices, pharmaceuticals, and nutritional products.

      SIEMENS HEALTHINEERS AG

      Siemens Healthineers AG is a Germany-based medical technology company founded in 1896 with 72,369 employees. As a public company, it manufactures and distributes diagnostic imaging, laboratory diagnostics, and point-of-care testing systems.

      DANAHER

      Danaher is a United States-based conglomerate founded in 1969 with 59,000 employees. As a public company, it operates across multiple sectors including life sciences, diagnostics, and environmental solutions.

      THERMO FISHER SCIENTIFIC INC.

      Thermo Fisher Scientific Inc. is a United States-based life sciences company founded in 1956 with 125,000 employees. As a public company, it provides laboratory equipment, reagents, and analytical instruments globally.

      REVVITY

      Revvity is a United States-based life sciences and diagnostics company founded in 1937 with 11,000 employees. As a public company, it manufactures and distributes analytical instruments and reagents for research and diagnostics.

      DIASORIN S.P.A.

      DiaSorin S.p.A. is an Italy-based diagnostics company founded in 1968 with 3,242 employees. As a public company, it develops and manufactures in vitro diagnostic products for clinical laboratories.

      BIO-RAD LABORATORIES, INC.

      Bio-Rad Laboratories, Inc. is a United States-based life sciences company founded in 1952 with 7,450 employees. As a public company, it manufactures and distributes reagents, instruments, and quality control products for clinical and research laboratories.

      QUIDELORTHO CORPORATION

      QuidelOrtho Corporation is a United States-based diagnostics company founded in 1979 with 6,500 employees. As a public company, it develops and manufactures rapid diagnostic tests and laboratory instruments.

      BIOMÉRIEUX

      bioMérieux is a France-based diagnostics company founded in 1963 with 14,894 employees. As a public company, it specializes in in vitro diagnostics for infectious diseases, industrial microbiology, and clinical diagnostics.

      QIAGEN

      QIAGEN is a Netherlands-based molecular diagnostics company founded in 1984 with 5,500 employees. As a public company, it develops and manufactures sample preparation and molecular testing solutions.

      SYSMEX CORPORATION

      Sysmex Corporation is a Japan-based diagnostics company founded in 1968 with 10,861 employees. As a public company, it manufactures and distributes hematology, hemostasis, and clinical chemistry analyzers.

      AGILENT TECHNOLOGIES, INC.

      Agilent Technologies, Inc. is a United States-based life sciences and diagnostics company founded in 1999 with 18,000 employees. As a public company, it provides analytical instruments, software, and services for research and diagnostics.

      SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.

      Shenzhen Mindray Bio-Medical Electronics Co., Ltd. is a China-based medical device company founded in 1991 with 21,288 employees. As a public company, it manufactures and distributes diagnostic imaging, patient monitoring, and laboratory instruments globally.

      North America vs. other regions

      HowNorth America compares to the other 3 regional blocs covered in this market.

      Global
      ~USD 2463.63 Million · 4.5% wtd CAGR ·
      Europe
      ~USD 550.79 Million · 5.3% wtd CAGR ·
      Asia Pacific
      ~USD 645.63 Million · 4.5% wtd CAGR ·

      Countries within North America - compare and drill down

      Country2025 size (native)
      USUSD 11474.68 Million
      CanadaUSD 1565.18 Million

      Country market size visualization

      US
      USD 11474.68 Million
      Canada
      USD 1565.18 Million

      Reasons to Buy this Report

      • Market Size & Growth Validation : Obtain precise 2025 baseline ($7.9B) and 2030 forecast data for North America, enabling accurate financial planning and investment decisions with region-specific growth rates exceeding global averages.
      • Country-Level Granularity : Access detailed market segmentation for US ($11.5B) and Canada ($1.6B), allowing targeted go-to-market strategies and resource allocation based on individual country dynamics and competitive landscapes.
      • Competitive Intelligence : Benchmark your immunoassay portfolio against North American market trends, identify white space opportunities, and understand regional regulatory requirements that differentiate this market from global competitors.
      • Strategic Planning & Forecasting : Leverage 5-year projections to guide R&D investments, manufacturing capacity planning, and partnership strategies aligned with North America's 7.4% CAGR and evolving diagnostic needs.
      • Stakeholder Alignment : Present data-backed market insights to boards, investors, and partners with credible regional forecasts that support expansion plans, M&A decisions, and commercial strategy in North America's high-value healthcare market.

      Frequently asked questions

      What is the current size of the Asia Pacific immunoassay market?

      The Asia Pacific immunoassay market is valued at $7,906.96 million in 2025 and is projected to reach $11,308.33 million by 2030.

      What is the expected growth rate for Asia Pacific immunoassay market?

      Asia Pacific's immunoassay market is expected to grow at a compound annual growth rate (CAGR) of 7.4% from 2025 to 2030.

      How does Asia Pacific immunoassay growth compare to global trends?

      Asia Pacific's 7.4% CAGR outpaces the global immunoassay market CAGR of 6.1%, indicating stronger regional expansion and market opportunity.

      Which countries are driving Asia Pacific immunoassay market growth?

      Key markets including China, India, Japan, and Southeast Asian nations are driving growth through healthcare infrastructure investment and rising diagnostic demand.

      What factors are accelerating immunoassay adoption in Asia Pacific?

      Rising chronic disease prevalence, increasing healthcare expenditure, government health initiatives, and demand for point-of-care testing are primary growth catalysts in Asia Pacific.

      RESEARCH METHODOLOGY

      This research study extensively used secondary sources, directories, and databases to identify and collect valuable information to analyze the global immunoassay market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative & quantitative information and assess the market's growth prospects. The global market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size.

      Secondary Research

      Secondary research was used primarily to identify & collect information for the extensive, technical, market-oriented, and commercial study. The secondary sources used for this study include annual reports, SEC filings, investor presentations, World Health Organization (WHO), United States Food and Drug Administration (US FDA), National Center for Biotechnology Information (NCBI), Health Canada, European Medicines Agency (EMA), and Centers for Disease Control and Prevention (CDC). These sources also obtained key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.

      Primary Research

      In-depth interviews were conducted with various primary respondents, including key industry players, subject-matter experts (SMEs), C-level executives of major market companies, and industry consultants, to gather and verify critical qualitative and quantitative information and evaluate the market prospects. Several primary sources from both the supply and demand sides of the market were interviewed to collect qualitative and quantitative data. The following is a breakdown of the primary respondents:

      Immunoassay Market

      To know about the assumptions considered for the study, download the pdf brochure

      Market Size Estimation

      Both top-down and bottom-up approaches were employed to estimate and verify the total size of the immunoassay market. These methods were also widely used to determine the sizes of various subsegments within the market. The research methodology used to estimate the market size includes the following:

      Immunoassay Market

      Data Triangulation

      The total market was divided into several segments and subsegments after determining the overall market size from the estimation process. Where applicable, data triangulation and market breakdown techniques were used to complete the overall market analysis and obtain precise statistics for all segments and subsegments. The data was triangulated by examining various factors and trends from both the demand and supply perspectives.

      Market Definition

      An immunoassay is a test that uses biochemistry to detect the presence or level of an analyte, which is a large protein or antibody produced in response to an infection. These assays are highly versatile and can be adapted to many formats based on user needs. Immunoassays have become popular and well-established procedures in laboratories. They rapidly and easily provide precise and accurate results. This technique is mainly used in clinical diagnostics, drug monitoring, drug discovery, and food testing.

      Stakeholders

      • Manufacturers and vendors of immunoassay instruments and consumables
      • Immunoassay product manufacturers
      • Diagnostic associations
      • Research associations involved in infectious and chronic disease research
      • Various research and consulting firms
      • Distributors of immunoassay instruments and consumables
      • Contract research manufacturers of immunoassays
      • Healthcare institutions
      • Clinical laboratories

      Report Objectives

      • To define, describe, and forecast the global immunoassay market by product, technology, specimen, application, end user, and region
      • To provide detailed information regarding the major factors influencing the growth of the market (such as drivers, restraints, challenges, and opportunities)
      • To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall immunoassay market
      • To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
      • To forecast the size of the market segments with respect to five regions: North America, Europe, the Asia Pacific, Latin America, the Middle East & Africa
      • To strategically profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
      • Track and analyze competitive developments such as acquisitions, product launches, expansions, agreements, partnerships, and R&D activities in the immunoassay market.
      • To analyze and provide funding & investment activities, brand/product comparative analysis, and vendor valuation & financial metrics of the immunoassay market.

      Customization Options

      With the given market data, MarketsandMarkets offers customizations per the company’s specific needs. The following customization options are available for this report:

      Portfolio Assessment

      • Product Matrix gives a detailed comparison of the product portfolios of the top five companies.

      Company Information

      • • Detailed analysis and profiling of additional market players (up to five).

      Geographical Analysis

      • A further breakdown of the Rest of European immunoassay market into countries
      • A further breakdown of the Rest of Asia Pacific immunoassay market into countries
      • A further breakdown of the Rest of Latin American immunoassay market into countries

      Get the Full Immunoassay Market Report

      Full forecast, segment splits, and company analysis for all Immunoassay Market.

      Need a Tailored Report?

      Customize this report to your needs

      Get 10% FREE Customization

      Customize This Report
      Fact checked
      DMCA.com Protection Status